Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

Naveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, Robert Z. Orlowski, Graciela M. Nogueras González, Veera Baladandayuthapani, Nitin Jain, Verena Wagner, Guillermo Garcia-Manero, Jatin Shah, Farhad Ravandi, Sherry Pierce, Koichi Takahashi, Naval Daver, Aziz Nazha, Srdan Verstovsek, Elias Jabbour, Marcos De Lima, Richard Champlin, Jorge CortesMuzaffar H. Qazilbash

Research output: Contribution to journalArticle

Abstract

Background Patients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. Patients and Methods Patients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS). Results The median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0%) initially received conventional chemotherapeutic agents, 7 (14.9%), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0%), a combination. Twenty patients (42.6%) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95% CI, 5.0-28.0). Of the 47 patients, 33 (70.2%) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4%) acute myeloid leukemia (t-AML), and 3 (6.4%) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8%) with t-MDS, 9 (81.8%) with t-AML, and 1 (33.3%) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95% CI, 4.0-8.7). Conclusion The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Multiple Myeloma
Acute Myeloid Leukemia
Second Primary Neoplasms
Therapeutics
Survival
Thalidomide
Hematopoietic Stem Cell Transplantation
Cytogenetics
Chromosome Aberrations

Keywords

  • Novel therapeutic agents
  • Overall survival
  • Second primary neoplasm
  • Therapy-related myeloid neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. / Pemmaraju, Naveen; Shah, Dhaval; Kantarjian, Hagop; Orlowski, Robert Z.; Nogueras González, Graciela M.; Baladandayuthapani, Veera; Jain, Nitin; Wagner, Verena; Garcia-Manero, Guillermo; Shah, Jatin; Ravandi, Farhad; Pierce, Sherry; Takahashi, Koichi; Daver, Naval; Nazha, Aziz; Verstovsek, Srdan; Jabbour, Elias; De Lima, Marcos; Champlin, Richard; Cortes, Jorge; Qazilbash, Muzaffar H.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 2, 01.02.2015, p. 110-114.

Research output: Contribution to journalArticle

Pemmaraju, N, Shah, D, Kantarjian, H, Orlowski, RZ, Nogueras González, GM, Baladandayuthapani, V, Jain, N, Wagner, V, Garcia-Manero, G, Shah, J, Ravandi, F, Pierce, S, Takahashi, K, Daver, N, Nazha, A, Verstovsek, S, Jabbour, E, De Lima, M, Champlin, R, Cortes, J & Qazilbash, MH 2015, 'Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia', Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 2, pp. 110-114. https://doi.org/10.1016/j.clml.2014.07.001
Pemmaraju, Naveen ; Shah, Dhaval ; Kantarjian, Hagop ; Orlowski, Robert Z. ; Nogueras González, Graciela M. ; Baladandayuthapani, Veera ; Jain, Nitin ; Wagner, Verena ; Garcia-Manero, Guillermo ; Shah, Jatin ; Ravandi, Farhad ; Pierce, Sherry ; Takahashi, Koichi ; Daver, Naval ; Nazha, Aziz ; Verstovsek, Srdan ; Jabbour, Elias ; De Lima, Marcos ; Champlin, Richard ; Cortes, Jorge ; Qazilbash, Muzaffar H. / Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. In: Clinical Lymphoma, Myeloma and Leukemia. 2015 ; Vol. 15, No. 2. pp. 110-114.
@article{3b014bcd450342bdbca9b7b72e6de6a2,
title = "Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia",
abstract = "Background Patients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. Patients and Methods Patients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS). Results The median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0{\%}) initially received conventional chemotherapeutic agents, 7 (14.9{\%}), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0{\%}), a combination. Twenty patients (42.6{\%}) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95{\%} CI, 5.0-28.0). Of the 47 patients, 33 (70.2{\%}) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4{\%}) acute myeloid leukemia (t-AML), and 3 (6.4{\%}) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8{\%}) with t-MDS, 9 (81.8{\%}) with t-AML, and 1 (33.3{\%}) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95{\%} CI, 4.0-8.7). Conclusion The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.",
keywords = "Novel therapeutic agents, Overall survival, Second primary neoplasm, Therapy-related myeloid neoplasm",
author = "Naveen Pemmaraju and Dhaval Shah and Hagop Kantarjian and Orlowski, {Robert Z.} and {Nogueras Gonz{\'a}lez}, {Graciela M.} and Veera Baladandayuthapani and Nitin Jain and Verena Wagner and Guillermo Garcia-Manero and Jatin Shah and Farhad Ravandi and Sherry Pierce and Koichi Takahashi and Naval Daver and Aziz Nazha and Srdan Verstovsek and Elias Jabbour and {De Lima}, Marcos and Richard Champlin and Jorge Cortes and Qazilbash, {Muzaffar H.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.clml.2014.07.001",
language = "English (US)",
volume = "15",
pages = "110--114",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

AU - Pemmaraju, Naveen

AU - Shah, Dhaval

AU - Kantarjian, Hagop

AU - Orlowski, Robert Z.

AU - Nogueras González, Graciela M.

AU - Baladandayuthapani, Veera

AU - Jain, Nitin

AU - Wagner, Verena

AU - Garcia-Manero, Guillermo

AU - Shah, Jatin

AU - Ravandi, Farhad

AU - Pierce, Sherry

AU - Takahashi, Koichi

AU - Daver, Naval

AU - Nazha, Aziz

AU - Verstovsek, Srdan

AU - Jabbour, Elias

AU - De Lima, Marcos

AU - Champlin, Richard

AU - Cortes, Jorge

AU - Qazilbash, Muzaffar H.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background Patients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. Patients and Methods Patients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS). Results The median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0%) initially received conventional chemotherapeutic agents, 7 (14.9%), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0%), a combination. Twenty patients (42.6%) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95% CI, 5.0-28.0). Of the 47 patients, 33 (70.2%) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4%) acute myeloid leukemia (t-AML), and 3 (6.4%) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8%) with t-MDS, 9 (81.8%) with t-AML, and 1 (33.3%) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95% CI, 4.0-8.7). Conclusion The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.

AB - Background Patients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. Patients and Methods Patients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS). Results The median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0%) initially received conventional chemotherapeutic agents, 7 (14.9%), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0%), a combination. Twenty patients (42.6%) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95% CI, 5.0-28.0). Of the 47 patients, 33 (70.2%) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4%) acute myeloid leukemia (t-AML), and 3 (6.4%) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8%) with t-MDS, 9 (81.8%) with t-AML, and 1 (33.3%) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95% CI, 4.0-8.7). Conclusion The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.

KW - Novel therapeutic agents

KW - Overall survival

KW - Second primary neoplasm

KW - Therapy-related myeloid neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84921763346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921763346&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.07.001

DO - 10.1016/j.clml.2014.07.001

M3 - Article

C2 - 25107338

AN - SCOPUS:84921763346

VL - 15

SP - 110

EP - 114

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -